News

SGMT
Sagimet Biosciences Inc. - Seri News

This news view pulls recent coverage and headlines tied to SGMT.

Latest Close

$10.88

1y Change

$4.12 (+60.95%)

Market Cap

$676,286,144.00

Sector

Healthcare

Industry

Biotechnology

Recommendation

strong_buy

Cantor Fitzgerald Initiates Coverage on Sagimet Biosciences With Overweight Rating

MT Newswires • Sep 9, 2026

Read article

Barclays Upgrades Sagimet Biosciences to Overweight From Equalweight, Adjusts Price Target to $18 From $8

MT Newswires • Sep 9, 2026

Read article

Sagimet Biosciences Announces Participation in Two Upcoming Investor Conferences

GlobeNewswire • Sep 2, 2026

Read article

Sagimet Biosciences Says US Late-Stage Trial of Denifanstat to Treat Acne on Track for Q4 Enrollment

MT Newswires • Aug 25, 2026

Read article

Sagimet Biosciences Advances AURORA U.S. Phase 3 Trial of Denifanstat in Acne Toward Patient Enrollment in Q4 2026

GlobeNewswire • Aug 25, 2026

Read article

Sagimet Biosciences Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire • Aug 17, 2026

Read article